|
 |
XyremThis page contains recent news articles, when available, and an overview of Xyrem but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Under the brand name Xyrem, Jazz markets sodium oxybate for the treatment of narcolepsy-associated cataplexy. Xyrem is a controlled substance and classed by ... Trading Markets (press release) Jazz Pharmaceuticals Submits New Drug Application for JZP-6 (sodium oxybate ... - Dec 15, 2009 Sodium oxybate is the active ingredient in XYREM®, approved by the FDA and marketed by Jazz Pharmaceuticals in the US for the treatment of excessive daytime ... CNNMoney.com (press release) Jeray wins tour card again after battling narcolepsy - Dec 20, 2009 But with a new medicine, Xyrem, a firm understanding of how her body works and the support of the Narcolepsy Action Network, Jeray has made strides that ... Dekalb Daily Chronicle Stock Watch: InvestorSoup.com Issues Market Alert for Jazz Pharmaceuticals Inc. - Dec 10, 2009 The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) ... Trading Markets (press release) Jazz Pharma 3Q loss narrows on Xyrem sales - Nov 6, 2009 Jazz Pharmaceuticals Inc. said late Thursday its third-quarter loss narrowed as sales of the sleep disorder treatment Xyrem climbed sharply. ... Forbes www.standoutstocks.com: Stocks That Stand Out For Nov. 9th, 2009 Are ZAGG ... - Nov 9, 2009 XYREM(R) (sodium oxybate) oral solution net sales for the third quarter of 2009 were $25.0 million, compared to $14.2 million for the third quarter of 2008, ... Trading Markets (press release) Jazz Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Nov 13, 2009 The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) ... PR-inside.com (press release) Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue ... - Oct 23, 2009 ...*Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem. *Pipeline analysis with detailed ... PR-Inside.com (Pressemitteilung) Possible Fibromyalgia Treatment Promising - Oct 20, 2009 Sodium oxybate is the active ingredient in the narcolepsy drug Xyrem, which already is a popular off-label treatment for fibromyalgia. ... About - News & Issues (blog) How Hard Should It Be to Imprison Someone for Telling the Truth? - Oct 20, 2009 Caronia was a sales representative for Xyrem, a sleep inducing depressant, whose principal ingredient was 8 UPDATE September/October 2009 www . fdli . org ... Linex Legal (registration) Forecast Insight Fibromyalgia Regulatory caution threatens EU market expansion ... - Oct 31, 2009 Datamonitor has marginally downgraded its sales forecast for Xyrem (sodium oxybate, Jazz Pharma and UCB). This stems from a newly-highlighted concern over ... PRMinds (press release) Jazz Pharmaceuticals Inc. Reports Operating Results (10-Q) - Nov 6, 2009 Although we do not expect royalty revenues to comprise a substantial portion of our revenues, we expect royalty revenues to increase as sales of Xyrem by ... GuruFocus.com Comedy is no laughing matter for Mike - Nov 9, 2009 ..."The best treatment at the moment is Xyrem, or GHB when you buy it on the street. It's controversial because of its association as a date rape drug. ... Shields Gazette BUYINS.NET: JAZZ, ITMN, HSTX, PDC, CHINA, ELON Expected To Be Lower After ... - Nov 2, 2009 The companyas marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for ... TMC Net Stocks That Stand Out For Nov. 9th, 2009 Are NUBL, HRRN, ERHE, NYMH, JAZZ - Nov 10, 2009 XYREM(R) (sodium oxybate) oral solution net sales for the third quarter of 2009 were $25.0 million, compared to $14.2 million for the third quarter of 2008, ... TMC Net FDA Has New Web Page for Select Medicine Disposal Instructions - Oct 20, 2009 Methadone Hydrochloride, Methadose, Morphine Sulfate, MS Contin, Onsolis, Opana, Opana ER, Oramorph SR, Oxycontin, Percocet, Percodan, and Xyrem. ... DOTmed.com (press release) Jazz Pharma 第三å£äº?æ?Ÿï¼Œè‚¡ä»·ä¸‹æŒ«7.6% - Nov 6, 2009 XYREM? (sodium oxybate)å?£æœ?è?¯å‰‚净销售é¢?为2500万美元，2008年第三å£ä¸º1420万美元。 å…?è´£å£°æ˜Žï¼šæœ¬æ–‡ä»…ä»£è¡¨ä½œè€…ä¸ªäººè§‚ç‚¹ï¼Œä¸Žå‡¤å‡°ç½‘æ— å…³ã€‚å…¶åŽŸåˆ›æ€§ä»¥å?Šæ–‡ä¸é™ˆè¿°æ–‡å—å’Œ ... 凤凰网 ΞαναγεννιοÏ?νται από τις στάχτες τους οι εταιÏ?είες βιοτεχνολογίας - Oct 19, 2009 Η Jazz Pharmaceuticals σκόÏ?αÏ?ε με αÏ?ξηση μεγαλÏ?τεÏ?η από 1.000% μετά την είδηση ότι το φάÏ?μακό της Xyrem για τη ναÏ?κοληψία μποÏ?εί να είναι αποτελεσματικό ... Healthview Manufacturer of Risky Drug to Sell Shares - May 31, 2007 Jazz sells it under the brand name Xyrem to treat narcolepsy, a serious sleep ... But the Food and Drug Administration has approved Xyrem for narcolepsy, ... New York Times ORPHAN MEDICAL SUBMITS XYREM SNDA TO FDA. - Mar 1, 2005 Orphan Medical, Inc. (Nasdaq:ORPH), Minneapolis, has submitted a Supplemental New Drug Application (sNDA) for Xyrem(R) (sodium oxybate) oral solution to the ... Entrepreneur Jazz settles, Orphan fined on Xyrem ads - Jul 13, 2007 PALO ALTO, Calif., July 13 (UPI) -- Jazz Pharmaceuticals has reached a deal with US authorities on charges stemming from its unit Orphan Medical's promotion ... United Press International Xyrem(R) (Sodium Oxybate) Now Available For The Treatment Of … - Mar 7, 2006 Jazz Pharmaceuticals announced today that Xyrem(R) (sodium oxybate) oral solution is now available for patients with narcolepsy who suffer from excessive ... Medical News Today - Medical News Today (press release) Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain in Patients ... - Feb 23, 2006 SAN DIEGO, Feb. 23 /PRNewswire/ -- Patients with fibromyalgia syndrome taking Xyrem(R) (sodium oxybate) in a Phase II clinical trial experienced significant ... RedOrbit Xyrem is Launched in Germany for the Treatment of Cataplexy in Adults... - Dec 8, 2005 Brussels, Belgium - December 8, 2005: UCB announced today that Xyrem (sodium oxybate) oral solution is now available in Germany for the treatment of ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Friday's Health Winners & Losers - Jan 12, 2007 Xyrem should be available to patients there in mid-2007. AstraZeneca's(AZN Quote) shares gained 2.6% to $56.49 after Bear Stearns upgraded the stock to ... TheStreet.com - TheStreet.com (subscription) Jazz to cut 24 pct jobs, take $1.9 mln charge in Q4 - Dec 16, 2008 Jazz currently markets Xyrem, a treatment for the sleep disorder narcolepsy, and Luvox CR, a drug to treat social anxiety disorder. ... Reuters Jazz Pharmaceuticals sees 2008 product sales of $90M-$120M - Mar 13, 2008 The company also said it expects 2008 sales of Xyrem, a treatment for excessive sleepiness, of $45 million to $55 million. ... Forbes Xyrem(R) (Sodium Oxybate) Receives FDA Approval for the Treatment of ... - Nov 22, 2005 PALO ALTO, Calif., Nov. 22 /PRNewswire/ -- Jazz Pharmaceuticals announced today that Xyrem(R) (sodium oxybate) oral solution has been approved for marketing ... Free with registration - PR Newswire - AccessMyLibrary.com … Pharmaceuticals announce expansion of Xyrem license agreement to … - Oct 3, 2006 UCB also adds new marketing territories under expanded agreement Brussels, Belgium and Palo Alto, California - October 3rd 2006 - 5:40 pm CET - UCB ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com New European Approval for Xyrem(R) Provides Significant Advance in … - Mar 12, 2007 The European Commission has approved Xyrem(R) (sodium oxybate) for the treatment of narcolepsy with cataplexy in adult patients. This new indication means ... Genetic Engineering News - Genetic Engineering News (press release) Xyrem(R) Is Launched In Germany For The Treatment Of Cataplexy In … - Dec 18, 2005 UCB announced today that Xyrem(R) (sodium oxybate) oral solution is now available in Germany for the treatment of cataplexy in adult patients with ... Medical News Today - Medical News Today (press release) Indictment of Doctor Tests Drug Marketing Rules - Jul 22, 2006 Dr. Peter Gleason, 53, promoted Xyrem for purposes other than those approved by the ... But any precedent could be complicated by the history of Xyrem, ... New York Times … Adopts Positive Opinion Recommending Approval of Xyrem(R) for the ... - Jan 25, 2007 Troy Cox, President CNS Operations, UCB said, 'This positive opinion is encouraging news and we now look forward to the opportunity of making Xyrem(R) ... Genetic Engineering News - Genetic Engineering News (press release) Orphan Medical Issues 2005 Xyrem Prescriptions Update - May 23, 2005 ORPHAN MEDICAL, INC. (Nasdaq:ORPH) announced that the total number of Xyrem(R) (sodium oxybate) oral solution prescriptions filled in the six-week period ... RedOrbit … Pharmaceuticals announce expansion of Xyrem® license agreement to ... - Mar 10, 2006 Under the agreement, UCB obtains the right to commercialize Xyrem® for the treatment of ... Jazz Pharmaceuticals markets Xyrem® in the United States. ... FinanzNachrichten.de Orphan Medical Submits Xyrem sNDA to Include Improvement in Other … - Jan 18, 2005 Orphan Medical, Inc. (Nasdaq:ORPH) announced today the submission of a Supplemental New Drug Application (sNDA) for Xyrem(R) (sodium oxybate) oral solution ... RedOrbit Orphan Medical fined $20M in Xyrem case.(Brief article) - Jul 23, 2007 Orphan Medical, a subsidiary of California, USA-based drugmaker Jazz Pharmaceuticals, has pleaded guilty in the US District Court in Brooklyn, New York, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Q4 2004 Orphan Medical Earnings Conference Call - Final. - Feb 16, 2005 Xyrem revenue was 10.6 million in 2004, growing by 165 percent over 2003. ... In addition to building Xyrem sales, our specialty sales force and marketing ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: Study Finds That Xyrem(R) (Sodium Oxybate) Relieves … - Feb 23, 2006 Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain in Patients With Fibromyalgia. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain and … - Nov 17, 2005 PALO ALTO, Calif., Nov. 17 /PRNewswire/ -- Patients with fibromyalgia syndrome taking Xyrem(R) (sodium oxybate) in a Phase II clinical trial experienced ... $4.95 - PR Newswire - ECNext Gran ill if she says 'I love you' - Jan 5, 2007 Xyrem is licensed in Britain but her local trust says it cannot afford it. Wendy said: “There is no cure but it could control the attacks.â€? ... The Sun Xyrem® Trial Currently Recruiting FM Patients in Many States - Oct 6, 2006 Should the pharmaceutical drug Xyrem® (sodium oxybate) become the first pharmaceutical drug approved by the FDA and other agencies for treatment of ... ProHealth International Approvals: Femara, Xyrem, Duodopa - Dec 12, 2005 Dec. 12, 2005 — The UK Medicines and Healthcare Products Regulatory Agency has approved letrozole tablets for the adjuvant treatment of postmenopausal women ... Medscape Indictment of Doctor Tests Drug Marketing Rules - Jul 24, 2006 But any precedent could be complicated by the history of Xyrem, which differs ... Because the active ingredient in Xyrem is gamma hydroxybutyrate, or GHB, ... $2.95 - Ocala Star-Banner - NewsBank Maker of risky narcolepsy drug plans IPO - May 30, 2007 Jazz sells it under the brand name Xyrem to treat narcolepsy. ... But the Food & Drug Administration has approved Xyrem for narcolepsy, and when dispensed ... New York Times (Euronext Brussels) - UCB : Xyrem® is Launched in Germany for the … - Sep 12, 2005 Brussels, Belgium - December 8, 2005: UCB announced today that Xyrem® (sodium oxybate) oral solution is now available in Germany for the treatment of ... euronext.com … Medical Announces Fourth Quarter 2004 Xyrem Prescription Levels Up... - Jan 20, 2005 MINNEAPOLIS -- Orphan Medical, Inc. (Nasdaq:ORPH) announced that 8928 Xyrem(R) prescriptions were filled during the fourth quarter ended December 31, 2004, ... $4.95 - Business Wire - ECNext Press Release: Xyrem(R) (Sodium Oxybate) Now Available for the … - Mar 6, 2006 Xyrem(R) (Sodium Oxybate) Now Available for the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Narcolepsy. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research New York Times Article Threatens Highly Successful Narcolepsy … - Jul 2, 2007 Just days before the manufacturer of the narcolepsy medication Xyrem made an ... The primary benefit of Xyrem over other sleep aids is that only Xyrem ... Free with registration - AScribe Medicine News Service - AccessMyLibrary.com … Announces European Commission Marketing Approval of Xyrem. - PR … - Dec 8, 2005 Xyrem is marketed in the European Union by UCB, which today announced the product's ... "Xyrem will be the first and only drug approved in Europe for the ... Pay-Per-View - PR Newswire - HighBeam Research United States 8th Circuit Court of Appeals Reports - LITTLE v.... - Aug 11, 2008 Orphan relied heavily on Xyrem, and it was uncertain whether Xyrem could have a ... If Xyrem successfully completed Phase II, it would have to proceed to, ... Pay-Per-View - United States 8th Circuit Court of... - Loislaw FDA Accepts Xyrem sNDA for Review, User Fee Deadline Set for … - Nov 18, 2005 Orphan Medical, Inc. (Nasdaq:ORPH) announced today that the Food and Drug Administration (FDA) has accepted for filing the Company's Supplemental New Drug ... RedOrbit Risky drug at center of offeringFirm's main product is GHB, with... - Jun 1, 2007 Jazz sells it under the brand name Xyrem to treat narcolepsy. ... But the Food and Drug Administration has approved Xyrem for narcolepsy, and when dispensed ... Pay-Per-View - International Herald Tribune - HighBeam Research FDA ACCEPTS XYREM SNDA FOR REVIEW. - May 1, 2005 Orphan Medical, Inc. (Nasdaq:ORPH) has announced that the Food and Drug Administration (FDA) has accepted for filing the company's Supplemental New Drug ... Entrepreneur … Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement … - Oct 3, 2006 UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement to Include Fibromyalgia Syndrome. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research International Approvals: Symbicort SMART, Alimta, Xyrem - Mar 19, 2007 March 19, 2007 — Health Canada has approved budesonide plus formoterol fumarate dehydrate inhalation aerosol with a flexible regimen for the maintenance and ... Medscape Off-Label Promotion Under Scrutiny by DOJ - Jun 1, 2008 Xyrem was approved for only two medical indications. The first, approved in July 2002, was for the treatment of cataplexy, a condition characterized by weak ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: Study Finds That Xyrem(R) (Sodium Oxybate) Relieves … - Nov 17, 2005 Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain and Improves Functioning in Patients Suffering From Fibromyalgia. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Clinical Trial to Study the Safety and Efficacy of Xyrem(R)... - Sep 7, 2006 ..."Data from a randomized controlled Phase II trial of Xyrem in treating fibromyalgia ... "We look forward to further evaluating the use of Xyrem in treating ... Free with registration - PR Newswire - AccessMyLibrary.com … Announces European Commission Marketing Approval of Xyrem - Dec 9, 2005 Xyrem is marketed in the European Union by UCB, which today announced the product's ... "Xyrem will be the first and only drug approved in Europe for the ... biotech-intelligence.com … Patient enrollment completed for Xyrem fibromyalgia syndrome... - Jan 10, 2005 2005 JAN 10 - (NewsRx.com & NewsRx.net) -- Orphan Medical, Inc. (Nasdaq:ORPH) announced that patient enrollment has been completed for its trial assessing ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Orphan Medical Issues Xyrem Prescriptions Update. - Feb 23, 2005 MINNEAPOLIS -- Orphan Medical, Inc. (Nasdaq:ORPH) announced that the total number of Xyrem(R) (sodium oxybate) oral solution prescriptions filled in the ... $4.95 - Business Wire - ECNext Valeant licenses Canada rights to Xyrem. - Jan 22, 2007 Valeant licenses Canada rights to Xyrem. Jazz Pharmaceuticals has signed an agreement licensing the Canadian marketing rights for its oral drug Xyrem ... $9.94 - Pharma Marketletter - Alacra Store Biogen Gains Rights To UCB's CDP323 In $200M Partnership - Oct 4, 2006 ...based Jazz Pharmaceuticals Inc. to obtain commercialization rights to Xyrem (sodium oxybate) for fibromyalgia syndrome upon approval in that indication. ... BioWorld Online - BioWorld Online UCB obtient des résultats positifs dans l'étude du Xyrem - Nov 24, 2008 Le groupe UCB et l'américain Jazz Pharmaceuticals ont enregistré de bons résultats dans la phase III de la recherche d'un médicament antidouleur pour les ... Express.be EC approves UCB's Xyrem. - Mar 19, 2007 EC approves UCB's Xyrem. The European Commission has approved Belgian drugmaker UCB's Xyrem (sodium oxybate) for the treatment of narcolepsy with cataplexy ... $9.94 - Pharma Marketletter - Alacra Store Business Update; FDA accepts Xyrem sNDA for review - Apr 19, 2005 2005 APR 19 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the US Food and Drug Administration (FDA) has accepted for filing the company's ... Pay-Per-View - Science Letter - Factiva, from Dow Jones ACORN HEART DEVICE FAILS TO WIN FDA PANEL OK - Jun 23, 2005 Orphan Medical's lead product is Xyrem, a treatment for a narcolepsy-related malady. The privately held Protomold Co., a Maple Plain-based maker of plastic ... $2.95 - St. Paul Pioneer Press - NewsBank Business Update; FDA accepts Xyrem sNDA for review - Apr 18, 2005 2005 APR 18 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the US Food and Drug Administration (FDA) has accepted for filing the company's ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Business Update; FDA accepts Xyrem sNDA for review - Apr 23, 2005 2005 APR 23 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the US Food and Drug Administration (FDA) has accepted for filing the company's ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Xyrem gains daytime claim.(Highlights) - Dec 1, 2005 Xyrem gains daytime claim: FDA cleared Jazz Pharmaceuticals' Xyrem (sodium oxybate) for ... Xyrem was previously approved for cataplexy in narcolepsy patients. Free with registration - Pharmaceutical Processing - AccessMyLibrary.com Article: FDA ACCEPTS XYREM SNDA FOR REVIEW. - Biotech Business | … - May 1, 2005 FDA ACCEPTS XYREM SNDA FOR REVIEW. ... find Biotech Business articles. Orphan Medical, Inc. (Nasdaq:ORPH) has announced that the Food and Drug ... Pay-Per-View - Biotech Business - HighBeam Research UCB meldt positieve resultaten voor Xyrem - Nov 21, 2008 Het Belgische UCB en het Amerikaanse Jazz Pharmaceuticals melden dat in de Phase III van het onderzoek naar een pijnstillend medicijn voor ... De Tijd ORPH Said FDA Accepts Xyrem sNDA for Review - Mar 21, 2005 Orphan Medical, Inc. (Nasdaq: ORPH) said the FDA has accepted for filing the Company's Supplemental New Drug Application for Xyrem oral solution. ... StreetInsider.com - StreetInsider.com (subscription) FDA Approvals: Effexor XR, Xyrem, Antara - Nov 28, 2005 Nov. 28, 2005 -- The US Food and Drug Administration (FDA) has approved extended-release venlafaxine HCl capsules for the treatment of adults with panic ... Medscape … indication for sodium oxybate: trial results lead Xyrem maker to... - Oct 1, 2005 ...find Clinical Psychiatry News articles. DENVER -- Sodium oxybate (Xyrem) is effective not only for cataplexy--its only approved indication at presen... Pay-Per-View - Clinical Psychiatry News - HighBeam Research EC approves UCB's Xyrem.(European Commission )(Brief article) - Mar 19, 2007 The European Commission has approved Belgian drugmaker UCB's Xyrem (sodium oxybate) for the treatment of narcolepsy with cataplexy in adult patients. ... $4.95 - Pharma Marketletter - ECNext Orphan Medical Reports 2005 First-Quarter Results; Product Revenues … - Apr 26, 2005 Xyrem revenue for the quarter was $3.9 million, an increase of $2.2 million, ... The Company submitted a sNDA for Xyrem to the FDA on January 18, 2005. ... $4.95 - Business Wire - ECNext … Patient enrollment completed for Xyrem fibromyalgia syndrome... - Jan 14, 2005 2005 JAN 14 - (NewsRx.com & NewsRx.net) -- Orphan Medical, Inc. (Nasdaq:ORPH) announced that patient enrollment has been completed for its trial assessing ... Pay-Per-View - Drug Week - Factiva, from Dow Jones FDA Accepts Xyrem sNDA for Review - Mar 23, 2005 The FDA has accepted for filing Orphan Medical's supplemental new drug application (sNDA) for Xyrem oral solution. Xyrem (sodium oxybate) is currently ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Narcolepsy; Pharma company releases number of Xyrem prescriptions … - Jan 2, 2005 2005 JAN 2 - (NewsRx.com & NewsRx.net) -- ORPHAN MEDICAL, INC., (Nasdaq:ORPH) announced that the total number of Xyrem (sodium oxybate) oral solution ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Xyrem gains daytime claim.(Highlights) | Article from Pharmaceutical ... - Dec 1, 2005 Xyrem gains daytime claim.(Highlights) ... find Pharmaceutical Processing articles. Xyrem gains daytime claim: FDA cleared Jazz Pharmaceuticals' Xyrem ... Pay-Per-View - Pharmaceutical Processing - HighBeam Research Press Release: Xyrem(R) (Sodium Oxybate) Receives FDA Approval for … - Nov 22, 2005 Xyrem(R) (Sodium Oxybate) Receives FDA Approval for the Treatment of Excessive Daytime Sleepiness in Patients With Narcolepsy. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research UCB's Xyrem gets CHMP recommendation. - Feb 5, 2007 UCB's Xyrem gets CHMP recommendation. Belgian biopharmaceutical company UCB says that the European Medicines Agency's (EMEA) Committee for Medicinal ... $9.94 - Pharma Marketletter - Alacra Store … expanded indication for Orphan Medical's Xyrem.(Food and Drug … - Mar 28, 2005 Xyrem is currently the only approved treatment for cataplexy, a sudden loss ... With clearance of the sNDA, Xyrem would become the first approved treatment ... $4.95 - Pharma Marketletter - ECNext Orphan sold to California company Minneapolis / St. Paul Business … - Apr 19, 2005 The company's recent financial improvement has been due largely to increased sales of the narcolepsy drug Xyrem. In the fourth quarter of 2004, Xyrem sales ... Twin Cities Business Journal UCB's Xyrem moves closer to EU approval.(Brief Article) - Jul 11, 2005 Belgian drugmaker UCB Pharma says that the European Committee for Medicinal Products for Human Use has recommended the award of a marketing authorization ... $4.95 - Pharma Marketletter - ECNext … Update; Pharmaceutical marketer issues Xyrem prescription sales... - Mar 26, 2005 2005 MAR 26 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the total number of Xyrem (sodium oxybate) oral solution prescriptions filled in a ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones … Update; Pharmaceutical marketer issues Xyrem prescription sales... - Mar 21, 2005 2005 MAR 21 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the total number of Xyrem (sodium oxybate) oral solution prescriptions filled in a ... Pay-Per-View - Pain & Central Nervous System Week - Factiva, from Dow Jones Orphan Medical's Xyrem effective in narcolepsy study.(Brief Article) - Nov 28, 2005 The National Fibromyalgia Association says that the results from a recent study of the narcolepsy drug Xyrem (sodium oxybate), which is marketed by Orphan ... $4.95 - Pharma Marketletter - ECNext … Update; Pharmaceutical marketer issues Xyrem prescription sales... - Mar 25, 2005 2005 MAR 25 - (NewsRx.com) -- Orphan Medical, Inc., (ORPH) announced that the total number of Xyrem (sodium oxybate) oral solution prescriptions filled in a ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Paralysed by saying I love you - Jan 4, 2007 The drug, marketed as Xyrem, has just been licensed in Britain after trials in the US but her local healthcare trust refuses to pay the £9000 a year it ... Metro Law.com - Judge Rejects Commercial Free Speech Defense in 'Off-Label'... - Sep 29, 2008 During October 2005, Caronia contends he received several calls from a confidential informant who wanted a presentation on Xyrem. ... Law.com Stocks on the Rise. - May 13, 2005 Xyrem revenue for the quarter was $3.9 million, an increase of $2.2 million, ... The Company submitted a sNDA for Xyrem to the FDA on January 18, 2005. ... $4.95 - M2 Presswire - ECNext Business & Finance; Pharma company announces fourth quarter 2004 … - Feb 18, 2005 He continued, "We anticipate Xyrem will grow at a high rate in 2006 with US Food and ... Xyrem contributed approximately $10.6 million to product revenue. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Business & Finance; Pharma company announces fourth quarter 2004 … - Feb 14, 2005 He continued, "We anticipate Xyrem will grow at a high rate in 2006 with US Food and ... Xyrem contributed approximately $10.6 million to product revenue. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones UCB breidt samenwerking rond Xyrem uit - Oct 3, 2006 BRUSSEL - Biofarmabedrijf UCB ondertekende een ruimere licentieovereenkomst met het Amerikaanse Jazz Pharmaceuticals voor het product Xyrem. ... Het Nieuwsblad Date-rape drug indictment: Doctor accused in illegal marketing of … - Apr 6, 2006 The active ingredient in Xyrem is GHB, a central nervous system ... The indictment charges that Gleason suggested to physicians that Xyrem was not a date ... Free with registration - Newsday - AccessMyLibrary.com Press Release: Jazz Pharmaceuticals and UCB Announce Positive … - Nov 20, 2008 Xyrem(R) (sodium oxybate) oral solution ... States by Jazz Pharmaceuticals and in Europe ... receiving Xyrem. Sodium oxybate, the active ... information. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Jazz Pharmaceuticals Announces Phase III Clinical... - Sep 7, 2006 ..."Data from a randomized controlled Phase II trial of Xyrem in treating fibromyalgia ... "We look forward to further evaluating the use of Xyrem in treating ... Pay-Per-View - PR Newswire - HighBeam Research Article: ORPHAN MEDICAL EXPECTS 2005 REVENUE TO EXCEED $35 … - Mar 1, 2005 Article: Orphan Medical Announces Positive Xyrem Clinical ... Business Wire; September 14, ... Article: ORPHAN MEDICAL CATAPLEXY DRUG XYREM APPROVED BY ... ... Pay-Per-View - Biotech Financial Reports - HighBeam Research Press Release: Jazz Pharmaceuticals Signs Licensing Agreement With … - Jan 12, 2007 Jazz Pharmaceuticals Signs Licensing Agreement With Valeant Pharmaceuticals for Canadian Marketing Rights to Xyrem(R). from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Orphan Europe SARL acquires Jazz Pharm-Cystadane Rights from Jazz … - Mar 7, 2007 Medicinal Products (COMP) has recommended Orphan Designation in Europe for Xyrem oral solution for… JAZZ PHARMACEUTICALS, INC.-DRUG PIPELINE ANALYSIS · JAZZ ... Pay-Per-View - deals - Alacra Store CEPHALON FILES FOR APPROVAL OF NEXT GENERATION PROVIGIL. - Apr 4, 2005 The FDA accepted for filing the supplemental NDA for Xyrem, which is approved for cataplexy, or sudden loss of muscle tone, in narcolepsy patients. ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones le Xyrem serait le premier m?dicament approuv? pour traiter la... - Feb 15, 2007 Selon les études réalisées au niveau européen, le Xyrem® a démontré son efficacité contre la cataplexie. Xyrem® a réduit jusqu'à plus de 69% (p= 0.0016) des ... Association Belge de narcolepsie Xyrem Studie - Wij zoeken vrijwilligers - May 13, 2007 Het is al een tijd dat we u hebben bericht omtrent een nieuwe studie met een geneesmiddel voor de behandeling van narcolepsie met cataplexie. ... Association Belge de narcolepsie Etude Xyrem - Appel ? volontaires - May 13, 2007 Nous vous parlons depuis pas mal de temps d'une étude portant sur un médicament qui devrait être mis sur le marché à la fin de cette année afin de traiter ... Association Belge de narcolepsie Press Release: Forest Laboratories, Inc. and Cypress Bioscience, Inc.... - May 22, 2007 Xyrem is currently marketed ... Americans with about 50000 patients receiving ... Article: UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) ... ... Pay-Per-View - PR Newswire - HighBeam Research Essais cliniques Xyrem au CHU de Liege - Feb 15, 2007 Le docteur Brigitte Stiels est en charge, à L'UCB, de la mise en place des essais cliniques permettant L'autorisation de mise en Vente du Xyrem sur le ... Association Belge de narcolepsie Test cliniques Xyrem au CHU de Li?ge - Mar 24, 2007 Ca y est, l'étude clinique portant sur le Xyrem va enfin se dérouler au CHU de Liège. Certains de nos membres ont déjà été contactés. ... Association Belge de narcolepsie Sodium oxybate may improve sleep in fibromyalgia patients.( … - Aug 1, 2008 DENVER -- Sodium oxybate (Xyrem) is effective not only . ... But prescriptions for sodium oxybate (Xyrem) will be restricted by several ... the day-long ... Pay-Per-View - Clinical Psychiatry News - HighBeam Research 17u30: UCB krijgt positief advies voor Xyrem - Jan 25, 2007 UCB deelde mee dat het Comité voor Geneesmiddelen voor Menselijk Gebruik (Committee for Medicinal Products for Human Use, CHMP) van het Europese ... Cash Loislaw Federal District Court Opinions - LITTLE GEM LIFE SCIENCES … - Feb 16, 2007 ...fn2] Orphan Medical's lead product was Xyrem (sodium oxybate) oral solution for the treatment ... Orphan Medical was also developing Xyrem for other uses. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Press Release: Jazz Pharmaceuticals, Inc. Completes Enrollment in... - Jun 2, 2008 September 7, 2006, Jazz Pharmaceuticals announced the initiation of its Phase III clinical development ... commercialization rights to Xyrem. ... Pay-Per-View - PR Newswire - HighBeam Research Narcolepsy Drug Gets Approval Recommendation - Jan 30, 2007 ...“With this expanded indication, Xyrem would be the first and only medicine ... Xyrem is indicated in Europe for the treatment of cataplexy in adult patients ... Sleep Review Jazz Pharmaceuticals to Pay $20 Million for Illegal Promotion of … - Jul 19, 2007 The company induced physicians to write prescriptions for Xyrem that were not ... Xyrem is approved to treat cataplexy and excessive daytime sleepiness in ... FDA news - FDA news (subscription) Press Release: Jazz Pharmaceuticals, Inc. Announces Final Patient Has... - Sep 11, 2008 Sodium oxybate is the active ingredient in Xyrem(R), a Jazz Pharmaceuticals product approved by the FDA for the treatment of excessive daytime sleepiness ... Pay-Per-View - PR Newswire - HighBeam Research Article: Buyout offer for Orphan Medical; The deal for the Minnetonka... - Apr 20, 2005 Article: Orphan Medical's Xyrem effective in narcolepsy ... Pharma Marketletter; November 28, 2005 ; 554 words ... ... results from a recent study of the ... Pay-Per-View - Star Tribune - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |